– First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile –

– First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam and Menarini, expanding treatment options for patients with elevated LDL-C –

FLORENCE, Italy, NAARDEN, Netherlands and MIAMI, Sept. 21, 2026 /PRNewswire/ — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, along with partner Menarini Group (“Menarini”), today announced that the European Commission (EC) has granted marketing authorization for Ubeslo® (obicetrapib 10 mg monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination) for patients with primary hypercholesterolaemia, both heterozygous familial (“HeFH”) and non-familial or mixed dyslipidaemia, marking the first regulatory approval of obicetrapib worldwide.

“The European Commission approval of Ubeslo and Evlarco marks a major milestone for NewAmsterdam as the first regulatory approval of obicetrapib globally, a novel oral therapy, and validates years of work focused on delivering a potential new treatment option for patients who continue to struggle to achieve recommended LDL-C levels despite previously available therapies,” said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma. “This first-in-class approval reflects the strength of the clinical evidence supporting obicetrapib, the dedication of our team and partners, and our commitment to addressing one of the largest unmet needs in cardiovascular medicine. Together with Menarini, we look forward to bringing Ubeslo and Evlarco to patients across Europe and building on this important milestone as we advance our vision of making obicetrapib available to patients around the world.”

The European Commission approval follows the positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) and is supported by data from NewAmsterdam’s comprehensive clinical development program evaluating obicetrapib, including the Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which demonstrated statistically significant LDL-C reductions of up to 40% with obicetrapib monotherapy versus placebo and approximately 50% with obicetrapib combined with ezetimibe versus placebo, with a tolerability profile comparable to placebo. NewAmsterdam and Menarini continue to advance the clinical development of obicetrapib through multiple ongoing Phase 3 trials, including PREVAIL, a cardiovascular outcomes trial, as well as REMBRANDT and RUBENS.

“This approval represents an important advancement for patients across Europe who require additional LDL-C lowering despite available therapies,” said Elcin Barker Ergun, Chief Executive Officer of Menarini Group. “We are proud to reach this significant achievement alongside NewAmsterdam and look forward to leveraging our well-established commercial capabilities and deep cardiovascular expertise to bring Ubeslo and Evlarco to healthcare providers and eligible patients throughout Europe.”

Under the parties’ licensing agreement, Menarini holds exclusive commercialization rights for obicetrapib in Europe and is responsible for regulatory interactions and commercialization activities throughout the region. NewAmsterdam is entitled to tiered double-digit percentage royalties ranging from the low double-digits to mid-twenties on net sales in the Menarini Territory and up to an additional €833 million upon the achievement of various clinical, regulatory and commercial milestones.

For full details on the approved indications, contraindications, warnings, and precautions please refer to the Summary of Product Characteristics (SmPC) which will be made available on the European Medicines Agency websites at:
https://www.ema.europa.eu/en/medicines/human/EPAR/ubeslo
https://www.ema.europa.eu/en/medicines/human/EPAR/evlarco 

About Obicetrapib

Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company’s Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company’s Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of Major Adverse Cardiovascular Events (“MACE”). The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company.

About Cardiovascular Disease

Cardiovascular disease remains the leading cause of death globally, despite the availability of lipid-lowering therapies (“LLTs”). By 2050 more than 184 million U.S. adults are expected to be affected by CVD and hypertension, including 27 million with coronary heart disease and 19 million with stroke. In the United States from 2019 through 2022, CVD age-adjusted mortality rates increased by 9%, reversing the trend observed since 2010 and undoing nearly a decade of progress. Despite the availability of high-intensity statins and non-statin LLTs, LDL-C target level attainment remains low, contributing to residual cardiovascular risk, and underscoring a significant clinical need for improved therapeutic regimens. Even with 269 million LLT prescriptions written over the last 12 months, 30 million under-treated US adults are not at their risk-based LDL-C goal, of which 13 million have ASCVD. Less than 1 in 4 patients with ASCVD achieve an LDL-C goal of less than 70 mg/dL and only 10% of very high risk ASCVD patients achieve the goal below 55 mg/dL. In addition to the 30 million under-treated U.S. adults, there are 10 million patients diagnosed with elevated LDL-C who are not taking any LLTs including statins. Beyond LDL-C, additional factors are at play, such as lifestyle choices, tobacco use, and obesity, as well as inflammation, thrombosis, triglyceride levels, elevated Lp(a) levels, and type 2 diabetes.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to build a new standard of care for people living with cardiometabolic disease. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.

About Menarini Group

The Menarini Group, with headquarters in Florence, is present in 140 countries worldwide to date, with $5.5 billion in consolidated turnover and more than 17,000 employees. Menarini’s products are present in the most important treatment areas, including those of cardiometabolic, oncology, gastroenterology, diabetology, pneumology, and anti-inflammatory/analgesic products. Through its commitment to R&D and high-quality manufacturing activities, Menarini continuously contributes to patients’ health worldwide, maintaining the highest quality standards.

Forward-Looking Statements

This press release contains “forward-looking” statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and are subject to the “safe harbor” provisions created thereunder. All statements that are not historical facts are hereby identified as forwarding-looking statements for this purposes and include, among others, statements relating to: the therapeutic potential of obicetrapib; expected availability of Ubeslo and Evlarco across Europe; the Company’s licensing agreement with Menarini and entitlement to potential future payments thereunder; the continued advancement of clinical development of obicetrapib through multiple ongoing Phase 3 trials; and other statements regarding the Company’s future operations, prospects, objectives, strategies and other future events. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These forward-looking statements are based upon management’s current expectations and assumptions. Actual results or events could differ materially and adversely from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various risks, uncertainties and other factors, including, among others: whether projections regarding clinical outcomes will reflect actual results in clinical use of Ubeslo and Evlarco; risks related to the Company’s ability to achieve its business plans, objectives and milestones, including those related to its licensing agreement with Menarini; challenges inherent to the clinical development and launch of new drug products; risks related to the Company’s reliance on third parties; and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, that are described in greater detail in the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 18, 2026 and in its Quarterly Report on Form 10-Q filed with the SEC on August 5, 2026, as well as in other filings the Company may make with the SEC in the future, which are available at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date of this press release, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of new information, future events, changed circumstances or otherwise, except as otherwise required by law.

BROADWAY (NCT05142722)
BROOKLYN (NCT05425745)
OCEAN NCT04770389
PREVAIL (NCT05202509)
REMBRANDT (NCT06305559)
ROSE NCT04753606
ROSE2 NCT05266586
RUBENS (NCT07219602)
TANDEM (NCT06005597)
TULIP NCT01970215

(Translations: in the event of any discrepancy, the English language version prevails)

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/menarini-group-and-newamsterdam-pharma-receive-european-commission-approval-for-ubeslo-obicetrapib-monotherapy-and-evlarco-obicetrapib-plus-ezetimibe-fixed-dose-combination-302884871.html

Company joins with Friends of Georgia State Parks for annual volunteer effort on September 26; New $10,000 donation to kickstart “Georgia in Color” initiative for color accessibility glasses

ATLANTA, Sept. 21, 2026 /PRNewswire/ — Georgia Power, the state’s leading electric utility serving customers in all but four Georgia counties, is proud to continue its longstanding partnership with Friends of Georgia State Parks & Historic Sites (Friends) – a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites.

This Saturday, September 26, hundreds of Georgia Power volunteers are expected to deploy for Your State Parks Day, an annual event hosted by Friends to clean up, beautify and care for Georgia’s state parks in celebration of National Public Lands Day. Fellow Georgians are also invited to join the volunteer event, or support the program in other ways by donating to Friends or simply sharing their favorite state parks memory. All of the information, including event and registration details by local state park, is available on the Friends of Georgia State Parks & Historic Sites website.

Georgia Power is also donating $10,000 to help kickstart a new fundraising effort by Friends to place free EnChroma color accessibility glasses in all Georgia State Parks for visitor use. For many people with red-green color vision deficiency, the vibrant colors of fall foliage, spring wildflowers, and Georgia’s scenic landscapes may appear less distinct. EnChroma glasses use specialized optical filters designed to enhance color contrast, helping many people distinguish certain colors more easily. Georgia Power’s donation follows a $25,000 donation at the end of 2025 to Friends to develop the program, and previous work with the Aimee Copeland Foundation to place all-terrain Trackchairs in Georgia State Parks for visitor use.

“Georgia’s state parks are a tremendous natural resource and asset for our state, driving travel and tourism for local communities and hosting millions of visitors each year,” said Trey Kilpatrick, senior vice president of External Affairs. “At Georgia Power, we’re committed to making our communities better because we are here. We’re excited to help more visitors enjoy a full experience through the Georgia in Color initiative, and to continue to partner with Friends of Georgia State Parks to protect and care for these special places so they can be enjoyed by Georgians and visitors from around the world for generations to come.”

“Georgia in Color is about helping more visitors fully experience the natural beauty of Georgia’s state parks,” said Damon Kirkpatrick, president and CEO of Friends of Georgia State Parks & Historic Sites. “Georgia Power’s generous investment in this initiative, together with the hands-on service of its volunteers, demonstrates a meaningful commitment to making these treasured places more accessible, welcoming, and enjoyable for everyone.”

Friends is a nonprofit organization with a mission to serve, support, and celebrate Georgia State Parks & Historic Sites. Statewide, Friends works to raise awareness of the economic and intrinsic values of Georgia’s greatest treasures. The organization works with state and community leaders to help make sure that Georgia’s natural and cultural resources are well protected, well maintained and well preserved for generations to come. At the local level, more than 50 chapters work with their respective sites to support individual projects and programs, with thousands of hours of volunteer time donated each year.

To learn more about Friends of Georgia State Parks & Historic Sites, and the organization’s Your State Parks Day program, visit: https://friendsofgastateparks.org/.

About Georgia Power 
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America’s premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company’s promise to 2.8 million customers in all but four of Georgia’s 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power offers rates below the national average, focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), X (X.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).

www.georgiapower.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/georgia-power-furthers-partnership-with-statewide-nonprofit-to-make-georgia-state-parks-more-accessible-and-enjoyable-302884857.html

SOURCE Georgia Power

Dual-Mode Label and Receipt Printing for Demanding Mobile Workflows

SHENZHEN, China, Sept. 21, 2026 /PRNewswire/ — HOIN today announced the launch of the HOP-HQ400, an industrial-grade 4-inch portable thermal printer designed for mobile printing in demanding work environments. Combining dual-mode label and receipt printing with a rugged protective design, flexible connectivity and broad system compatibility, the HOP-HQ400 is built to support logistics, warehousing, delivery, retail and outdoor field operations.

One Printer for Labels and Receipts

The HOP-HQ400 supports both label and receipt printing, allowing users to switch modes according to the task at hand. Receipt printing supports widths of 58mm, 80mm and 104mm, while label printing supports widths from 20mm to 108mm. This flexible media range helps businesses handle different ticket, label and on-site printing requirements with one portable device.

From warehouse identification and logistics operations to courier documents, food-delivery orders, supermarket receipts and outdoor field work, the HOP-HQ400 is designed to simplify mobile printing workflows and reduce the need to switch between devices.

Rugged Protection for Challenging Field Conditions

To help withstand the demands of mobile operations, the HOP-HQ400 features a protective edge-wrapped design and a drop-resistant structure. It supports a 1.5-meter drop resistance rating and an IP56 water-resistance rating, providing added protection against accidental drops and wet working conditions.

“Portable printers get used in ways desktop printers never do,” said Nina Xia, co-founder of HOIN. “The HOP-HQ400 came out of conversations with customers in outdoor delivery and logistics who needed hardware that could handle the environment, not just the print job.”

Fast Output and Flexible Connectivity

The HOP-HQ400 uses an imported Japanese print mechanism and delivers print speeds of up to 100mm/s. A high-power 5200 battery and Type-C interface support mobile use and convenient charging.

The printer offers a range of connectivity options, including USB, Bluetooth, LAN and Wi-Fi. It supports Windows, Android, iOS, Mac and Linux systems, helping customers integrate the device into different terminals and business workflows.

The HOP-HQ400 also supports automatic paper detection and positioning, as well as 1D and 2D barcode printing, helping users improve printing accuracy and on-site processing efficiency.

A 0.96-Inch Display for Easier Setup

A 0.96-inch display enables users to adjust print density, calibrate paper and change interface modes directly on the device. These controls help simplify configuration and reduce operating steps in complex field environments.

Command-Set Compatibility for Customer Integration

For customers that need to integrate the printer into existing software or develop customized applications, the HOP-HQ400 supports TSPL, CPCL and ESC/POS command sets. This compatibility helps customers connect the printer with established systems and adapt it to different application scenarios.

Designed for Multi-Industry Mobile Printing

With dual-mode printing, industrial-grade protection, multiple connectivity options and broad operating-system compatibility, the HOP-HQ400 is designed for applications including:

Logistics and warehousing: on-site labels, cargo identification and work documents.Courier and food delivery: mobile waybills, order receipts and delivery-related information.Supermarkets and retail: receipts and labels in different supported widths.Outdoor and high-altitude operations: on-site printing in mobile, complex or wet environments.

About HOIN

Shenzhen Hoin Electronic Technology Co., Ltd.(HOIN) is a manufacturer of Thermal Printer, Thermal Label Printer, Thermal Transfer Printer, Thermal Barcode Label Printer, Barcode Printer, and portable printing solutions. Established in 2015 and operating from a 10,000㎡ facility in Baoan, Shenzhen, the company serves clients across more than 50 countries in telecom, logistics, retail, and industrial sectors. Certifications include ISO9001:2015, CE, FCC, BSCI, RoHS, CCC, CB, and BIS.

Media Contact:
Person: Nina Xia
Email: nina.xia@hoinprinter.com 
Company: Shenzhen Hoin Electronic Technology Co., Ltd.
Official Website: https://www.hoinprinter.com/ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hoin-launches-hop-hq400-industrial-grade-drop-resistant-and-water-resistant-4-inch-portable-thermal-printer-302884535.html

SOURCE Shenzhen Hoin Electronic Technology Co., Ltd.